PFIZER BREAKTHROUGH GROWTH INITIATIVE
The Pfizer Breakthrough Growth Initiative will focus on making non-controlling equity investments in clinical-stage public companies, with a primary focus on companies with small- to medium-sized market capitalizations across a range of therapeutic categories that are consistent with Pfizer’s core areas of focus: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Hospital.
PFIZER BREAKTHROUGH GROWTH INITIATIVE
Founded:
2020-06-01
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-13 | AgomAb Therapeutics | Pfizer Breakthrough Growth Initiative investment in Series B - AgomAb Therapeutics | 38.4 M EUR |
| 2022-06-16 | Akero Therapeutics | Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Akero Therapeutics | 25 M USD |
| 2021-11-18 | Cardiff Oncology | Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Cardiff Oncology | 15 M USD |
| 2021-01-12 | ESSA Pharma | Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - ESSA Pharma | 10 M USD |
| 2021-01-12 | Vedanta Biosciences | Pfizer Breakthrough Growth Initiative investment in Venture Round - Vedanta Biosciences | 25 M USD |
| 2020-11-09 | Homology Medicines | Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Homology Medicines | 60 M USD |
| 2020-09-08 | Trillium Therapeutics | Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Trillium Therapeutics | 25 M USD |